TRIPP Wants You to ‘Be Here Now,’ With or Without Ram Dass
Psychedelic Spotlight trips with Ram Dass at the 50th anniversary celebration of the spiritual teacher’s iconic book.
Psychedelic Spotlight News
-
-
Lil Nas X Says Psychedelics Helped Him ‘Open Up’ to Write Debut Album ‘Montero’
Pop star says in new interview that tripping on psilocybin enabled him, for the first time, to “write actual stories about my life and put it into my music.”
-
Can the Psychedelics Boom Go Bust? A Conversation with Cybin Chief Clinical Officer Dr. Alex Belser
“Something that people used to speak about only in whispers is now standard policy,” says the psychedelics researcher, with 20 years of experience, in a wide-ranging Q&A.
-
Parents Are Very Open to Ketamine Therapy for Kids, Study Finds
“As parents maintain decision-making capacity of their child’s medical care, parental consent is a key factor in the adoption of new treatments for adolescents,” study authors explain.
-
Are We Being Exposed to Psychedelics More Than Ever Before? Survey Says…It’s Complicated
A study of American newspaper mentions of psychedelics doesn’t stack up to what leaders in the industry are observing in the media landscape at large.
-
NEW MindMed MDMA trials, Compass Pathways Patent, Small Pharma DMT Trials Begins | MNMD, CMPS, DMT
NEW MindMed MDMA trials, Compass Pathways Patent, Small Pharma DMT Trials Begins | MNMD, CMPS, DMT
What’s up psychedelic investors! We have been seeing a lot of red in the last few months. Companies like MindMed (MNMD: NASDAQ) (MMED:NEO), Compass Pathways (CMPS: NASDAQ) &Small Pharma ( OTC: DMTTF) ( CVE: DMT) have had huge news in the last week. So in this episode we’ll be covering the major news surrounding these psychedelic stocks!
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestorWant to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.comMusic from:
www.bensound.comVideo editing: @themyaholy
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #CompassPathways #PsychedelicStocks
-
Forgotten Psychedelics: LSA — Also Known as Ololiuqui
Meet LSA: LSD’s less intense but introspective cousin found in the seeds of morning glories and other plants. Here’s everything you need to know about the origins, effects, and uses of LSA.
-
Psychedelic Business Spotlight: October 29
This week in psychedelic business news: MindMed’s MDMA research pipeline to treat Autism Spectrum Disorder; Cybin EMBARKs; Awakn and MindCure partner to heal alcoholism.
-
Psychedelic Users Experienced Less Psychological Stress During COVID-19 Lockdowns, Study Finds
Researchers found stress further reduced for the participants that use psychedelic drugs at least once every six months.
-
Driver’s Licenses to Trip on Psychedelics by 2035? Rick Doblin Maps Out the Future of ‘Spiritualized Humanity’
The MAPS founder, who will speak at psychedelic conference Wonderland Miami next month, predicts clinics that administer the medicines will become licensing bodies for personal use.
